Suppr超能文献

爱尔兰首选药物倡议(2011 - 2016年)内索赔的处方趋势和模式评估:一项中断时间序列研究。

An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (20112016): an interrupted time-series study.

作者信息

McDowell Ronald, Bennett Kathleen, Moriarty Frank, Clarke Sarah, Barry Michael, Fahey Tom

机构信息

HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland Medical School, Dublin, Ireland.

Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

出版信息

BMJ Open. 2018 Apr 20;8(4):e019315. doi: 10.1136/bmjopen-2017-019315.

Abstract

OBJECTIVE

To examine the impact of the Preferred Drugs Initiative (PDI), an Irish health policy aimed at enhancing evidence-based cost-effective prescribing, on prescribing trends and the cost of prescription medicines across seven medication classes.

DESIGN

Retrospective repeated cross-sectional study spanning the years 20112016.

SETTING

Health Service Executive Primary Care Reimbursement Service pharmacy claims data for General Medical Services (GMS) patients, approximately 40% of the Irish population.

PARTICIPANTS

Adults aged ≥18 years between 2011 and 2016 are eligible for the GMS scheme.

PRIMARY AND SECONDARY OUTCOMES

The percentage of PDI medications within each drug class per calendar quarter. Linear regression was used to model prescribing of the preferred drug within each medication group and to assess the impact of PDI guidelines and other relevant changes in prescribing practice. Savings in drug expenditure were estimated.

RESULTS

Between 2011 and 2016, around a quarter (23.59%) of all medications were for single-agent drugs licensed in the seven drug classes. There was a small increase in the percentage of PDI drugs, increasing from 4.64% of all medications in 2011 to 4.76% in 2016 (P<0.001). The percentage of preferred drugs within each drug class was significantly higher immediately following publication of the guidelines for all classes except urology, with the largest increases noted for lansoprazole (1.21%, 95% CI: 0.84% to 1.57%, P<0.001) and venlafaxine (0.71%, 95% CI: 0.15% to 1.27%, P=0.02). Trends in prescribing of the preferred drugs between PDI guidelines and the end of 2016 varied between drug classes. Total cost savings between 2013 and 2016 were estimated to be €2.7 million.

CONCLUSION

There has been a small increase in prescribing of PDI drugs in response to prescribing guidelines, with inconsistent changes observed across therapeutic classes. These findings are relevant where health services are seeking to develop more active prescribing interventions aimed at changing prescribing practice.

摘要

目的

研究爱尔兰一项旨在加强循证性成本效益处方开具的卫生政策——首选药物倡议(PDI)对七个药物类别的处方开具趋势和处方药成本的影响。

设计

2011年至2016年的回顾性重复横断面研究。

背景

卫生服务执行局初级医疗报销服务中针对普通医疗服务(GMS)患者的药房报销数据,这些患者约占爱尔兰人口的40%。

参与者

2011年至2016年间年龄≥18岁的成年人有资格参加GMS计划。

主要和次要结果

每个日历季度各药物类别中PDI药物的百分比。采用线性回归对每个药物组中首选药物的处方开具进行建模,并评估PDI指南及处方实践中其他相关变化的影响。估计药物支出节省情况。

结果

2011年至2016年期间,所有药物中约四分之一(23.59%)是用于七个药物类别中获批的单药。PDI药物的百分比略有增加,从2011年所有药物的4.64%增至2016年的4.76%(P<0.001)。除泌尿科外,各药物类别指南发布后,首选药物的百分比均显著高于发布前,兰索拉唑(1.21%,95%置信区间:0.84%至1.57%,P<0.001)和文拉法辛(0.71%,95%置信区间:0.15%至1.27%,P=0.02)的增幅最大。PDI指南发布至2016年底期间,各药物类别首选药物的处方开具趋势有所不同。2013年至2016年估计共节省成本270万欧元。

结论

响应处方指南,PDI药物的处方开具略有增加,各治疗类别变化不一致。这些发现对寻求制定旨在改变处方实践的更积极处方干预措施的卫生服务机构具有参考意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d8f/5914712/ddf8ee3a9100/bmjopen-2017-019315f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验